Cardiovascular risk and outcomes in symptomatic patients with suspected coronary artery disease and non coronary vascular disease: A report from the PROMISE trial - 30/10/21
, Amanda Stebbins, MS a, W. Schuyler Jones, MD a, b, J. Antonio Gutierrez, MD, MHS a, b, Manesh R. Patel, MD a, b, Rowena J. Dolor, MD, MHS a, c, Patricia A. Pellikka, MD d, Brooke Alhanti, PhD a, Udo Hoffmann, MD e, Pamela S. Douglas, MD a, bRésumé |
Background |
Non-coronary vascular disease (NCVD) is associated with adverse cardiovascular events. Little is known about physician risk assessment, prevalence of coronary artery disease (CAD), cardiac catheterization, and the performance of the atherosclerotic cardiovascular disease (ASCVD) risk score in patients with NCVD.
Methods |
Retrospective analysis of outpatients with angina and no known CAD from the PROMISE trial. NCVD included carotid artery stenosis ≥50%, or history of stroke or peripheral artery disease. Multivariable models of physician estimates of the probability of obstructive CAD, prevalence of non-obstructive and obstructive CAD, referral to cardiac catheterization, and all-cause death/myocardial infarction/unstable angina were performed.
Results |
Among 10,001 patients in the PROMISE trial, 379 (3.8%) patients had NCVD. Only 8.5% of participants with NCVD were categorized as high-risk for obstructive CAD by physicians, though 15.5% (25/161) had obstructive CAD in those randomized to coronary computed tomography (CTA). NCVD was independently associated with non-obstructive (aOR = 1.58; 95% CI 1.18-2.61; P = .006) but not obstructive CAD by CTA. Adjusted referral to cardiac catheterization was similar with and without NCVD (aOR 1.04; 95% CI 0.88-1.94, P = .19). NCVD was associated with an increased risk of all-cause death/MI/UA (aOR 2.03; 95% CI 1.37-3.01, P < .001). There was no interaction between NCVD status and ASCVD risk score.
Conclusions |
Among patients with NCVD and angina, NCVD had increased adjusted risks of CAD and adverse outcomes which were not well described by ASCVD risk score and were underrecognized by physicians. Increased awareness and better risk stratification tools for patients with NCVD may be necessary to recognize the associated CV risk and optimize diagnostic testing and therapies.
Le texte complet de cet article est disponible en PDF.Plan
| This paper was handled by Guest Editor (Debabrata Mukherjee, MD. Clin. Inv.). |
Vol 242
P. 82-91 - décembre 2021 Retour au numéro
Article précédent
- Cardiovascular and major bleeding outcomes with antiplatelet and direct oral anticoagulants in patients with acute coronary syndrome and atrial fibrillation: A population-based analysis
- Ghadeer K. Dawwas, Geoffrey D. Barnes, Eric Dietrich, Adam Cuker, Charles E. Leonard, Michael V. Genuardi, James D. Lewis
- Initial rhythm control with cryoballoon ablation vs drug therapy: Impact on quality of life and symptoms
- Nikola Pavlovic, Gian-Battista Chierchia, Vedran Velagic, Jean Sylvain Hermida, Stewart Healey, Giuseppe Arena, Nicolas Badenco, Christian Meyer, Jian Chen, Saverio Iacopino, Frédéric Anselme, Lukas Dekker, Fernando Scazzuso, Douglas L Packer, Carlo de Asmundis, Heinz-Friedrich Pitschner, Fabio Di Piazza, Rachelle E Kaplon, Malte Kuniss, Cryo-FIRST Investigators
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?